Target type: cellularcomponent
A transmembrane, G protein-coupled signaling receptor complex which is capable of adrenomedullin receptor activity. [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:22102369]
The adrenomedullin receptor complex is a multi-protein complex responsible for the signal transduction of adrenomedullin, a potent vasodilator peptide. The complex consists of three main components:
1. **Calcitonin receptor-like receptor (CLR)**: This is the primary receptor protein that binds adrenomedullin. It is a seven-transmembrane G protein-coupled receptor (GPCR) and belongs to the family of calcitonin receptors.
2. **Receptor activity-modifying protein 1 (RAMP1)**: RAMP1 is a single-transmembrane protein that associates with CLR and is essential for the formation of a functional adrenomedullin receptor complex. RAMP1 interacts with CLR through its extracellular domain and modulates the binding affinity and signaling properties of the complex.
3. **G protein:** Upon adrenomedullin binding, the CLR-RAMP1 complex activates a specific type of G protein, typically Gαs. This G protein is a heterotrimeric complex consisting of alpha, beta, and gamma subunits. The activated Gαs subunit then interacts with adenylate cyclase, leading to the production of cyclic AMP (cAMP), a second messenger molecule that mediates downstream signaling events.
The cellular component of the adrenomedullin receptor complex can be localized to the plasma membrane of various cell types, including vascular endothelial cells, smooth muscle cells, and neurons. It plays a crucial role in regulating blood pressure, vascular tone, and other physiological processes.'
"
Protein | Definition | Taxonomy |
---|---|---|
Calcitonin gene-related peptide type 1 receptor | A calcitonin gene-related peptide type 1 receptor that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q16602] | Homo sapiens (human) |
Receptor activity-modifying protein 3 | A receptor activity-modifying protein 3 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O60896] | Homo sapiens (human) |
Receptor activity-modifying protein 2 | A receptor activity-modifying protein 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O60895] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
azaperone | azaperone : An N-arylpiperazine that is 2-(piperazin-1-yl)pyridine in which the amino hydrogen is replaced by a 3-(4-fluobenzoyl)propyl group. Used mainly as a tranquiliser for pigs and elephants. Azaperone: A butyrophenone used in the treatment of PSYCHOSES. | aminopyridine; aromatic ketone; monofluorobenzenes; N-alkylpiperazine; N-arylpiperazine; tertiary amino compound | antipsychotic agent; dopaminergic antagonist |
telcagepant | telcagepant: structure in first source | ||
mk 3207 | |||
bms 694153 | |||
(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta(b)pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxylate | |||
mk-8825 | |||
atogepant | atogepant : A secondary carboxamide resulting from the formal condensation of the carboxy group of (3'S)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylic acid with the amino group of (3S,5S,6R)-3-amino-6-methyl-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-2-one. It is a selective oral, small-molecule antagonist of calcitonin gene-related peptide (CGRP) receptor that has been approved for the treatment of migraine. | azaspiro compound; organic heterotetracyclic compound; piperidones; secondary carboxamide; trifluorobenzene | calcitonin gene-related peptide receptor antagonist |